The HER2DX genomic test integrates clinical and genomic information from patients with HER2+ breast cancer to estimate the risk of recurrence and response to treatment. The test, which analyzes the expression of 27 genes in a tumor sample, captures biological processes of interest for cancer progression. The results are published in eBioMedicine.
Read the full article in Genotipia.com
Comments are closed.